Metropolis Healthcare Intrinsic Value
Metropolis Healthcare intrinsic value. Metropolis Healthcare (METROPOLIS) median intrinsic value is ₹726.19 from 10 valuation models (range ₹168–₹1117), vs current price ₹558.70 — +30.0% upside (Trading Below Calculated Value), margin of safety 23.1%. Analyse METROPOLIS FII DII holdings to track promoter, FII and institutional holdings.
METROPOLIS Valuation Methods Summary — DCF, Graham Number & P/E
Metropolis Healthcare intrinsic value across 10 models vs current price ₹558.70 — upside/downside and value range per method. Browse METROPOLIS income statement for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹320.32 | ₹256.26 - ₹384.38 | -42.7% | EPS: ₹14.56, Sector P/E: 22x |
| Book Value Method | asset | ₹726.19 | ₹653.57 - ₹798.81 | +30.0% | Book Value/Share: ₹363.10, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹961.90 | ₹865.71 - ₹1058.09 | +72.2% | Revenue/Share: ₹480.95, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1117.40 | ₹1005.66 - ₹1229.14 | +100.0% | EBITDA: ₹572.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹889.37 | ₹711.50 - ₹1067.24 | +59.2% | CF Growth: 8.5%, Discount: 15% |
| PEG Ratio Method | growth | ₹167.61 | ₹150.85 - ₹184.37 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹224.95 | ₹202.45 - ₹247.45 | -59.7% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹1013.33 | ₹912.00 - ₹1114.66 | +81.4% | ROE: 19.9%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹344.89 | ₹310.40 - ₹379.38 | -38.3% | EPS: ₹14.56, BVPS: ₹363.10 |
| Dividend Yield Method | dividend | ₹200.00 | ₹180.00 - ₹220.00 | -64.2% | DPS: ₹5.00, Target Yield: 2.5% |
METROPOLIS Intrinsic Value vs Market Price — All Valuation Models
Metropolis Healthcare fair value range ₹168–₹1117 vs current market price ₹558.70 across 10 valuation models. For current market price and key ratios, visit METROPOLIS share price screener.
METROPOLIS Intrinsic Value Analysis — Undervalued or Overvalued?
Metropolis Healthcare median intrinsic value ₹726.19, current price ₹558.70 — Trading Below Calculated Value by 30.0%, margin of safety 23.1%.
What is the intrinsic value of METROPOLIS?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Metropolis Healthcare (METROPOLIS) is ₹726.19 (median value). With the current market price of ₹558.70, this represents a +30.0% variance from our estimated fair value.
The valuation range spans from ₹167.61 to ₹1117.40, indicating ₹167.61 - ₹1117.40.
Is METROPOLIS undervalued or overvalued?
Based on our multi-method analysis, Metropolis Healthcare (METROPOLIS) appears to be trading below calculated value by approximately 30.0%.
METROPOLIS Financial Health — Key Ratios vs Industry Benchmarks
Metropolis Healthcare financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 19.9% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 27.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.94x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
METROPOLIS Cash Flow Quality — Operating & Free Cash Flow
Metropolis Healthcare operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹351 Cr | ₹241 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹263 Cr | ₹164 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹264 Cr | ₹220 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹247 Cr | ₹247 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹253 Cr | ₹-115 Cr | Positive Operating Cash Flow | 6/10 |